145 related articles for article (PubMed ID: 36754615)
21. Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab.
Popović A; Petković I; Dimitrijevic A; Jović A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):86-91. PubMed ID: 38006368
[TBL] [Abstract][Full Text] [Related]
22. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
[TBL] [Abstract][Full Text] [Related]
23. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.
Hou Y; Li X; Yang Y; Shi H; Wang S; Gao M
Front Immunol; 2023; 14():1274431. PubMed ID: 38022654
[TBL] [Abstract][Full Text] [Related]
24. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
25. Increased circulating TGF-β1 is associated with impairment in NK cell effector functions in metastatic melanoma patients.
Mirjačić Martinović K; Vuletić A; Mališić E; Srdić-Rajić T; Tišma Miletić N; Babović N; Jurišić V
Growth Factors; 2022 Nov; 40(5-6):231-239. PubMed ID: 36129407
[TBL] [Abstract][Full Text] [Related]
26. Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer.
Qi Q; Peng Y; Zhu M; Zhang Y; Bao Y; Zhang X; Zhang J; Liu Y
Int Immunopharmacol; 2023 Jan; 114():109553. PubMed ID: 36516540
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.
Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R
Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702
[TBL] [Abstract][Full Text] [Related]
28. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
[TBL] [Abstract][Full Text] [Related]
29. [Expression level of cytokines in patients with sepsis and its effect on prognosis].
Li P; Yang H; Cui Q; Ma N; Liu Q; Sun X; Sun R
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Dec; 35(12):1250-1254. PubMed ID: 38149385
[TBL] [Abstract][Full Text] [Related]
30. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
31. [Expression and Prognostic Value of Cytokines in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma].
Man Y; Ge CQ; Li ZZ; Yang TH; Wang YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1050-1055. PubMed ID: 37551476
[TBL] [Abstract][Full Text] [Related]
32. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.
Mirjačić Martinović K; Babović N; Džodić R; Jurišić V; Matković S; Konjević G
J Transl Med; 2015 Apr; 13():120. PubMed ID: 25889680
[TBL] [Abstract][Full Text] [Related]
33. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
34. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
35. Dynamic changes of soluble HLA-G and cytokine plasma levels in cervical cancer patients: potential role in cancer progression and immunotherapy.
Xu HH; Xie YY; Jun-Gan ; Yang Z; Han QY
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4195-4204. PubMed ID: 36053326
[TBL] [Abstract][Full Text] [Related]
36. Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR; Verkhovskaia S; Mastroeni S; Carbone ML; Abeni D; Di Rocco CZ; Samà N; Zappalà AR; Marchetti P; De Galitiis F; Failla CM; Fortes C
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e18-e24. PubMed ID: 34563446
[TBL] [Abstract][Full Text] [Related]
37. Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.
Mancuso F; Lage S; Rasero J; Díaz-Ramón JL; Apraiz A; Pérez-Yarza G; Ezkurra PA; Penas C; Sánchez-Diez A; García-Vazquez MD; Gardeazabal J; Izu R; Mujika K; Cortés J; Asumendi A; Boyano MD
Mol Oncol; 2020 Aug; 14(8):1705-1718. PubMed ID: 32485045
[TBL] [Abstract][Full Text] [Related]
38. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
[TBL] [Abstract][Full Text] [Related]
39. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study.
Sánchez-Zauco N; Torres J; Gómez A; Camorlinga-Ponce M; Muñoz-Pérez L; Herrera-Goepfert R; Medrano-Guzmán R; Giono-Cerezo S; Maldonado-Bernal C
BMC Cancer; 2017 May; 17(1):384. PubMed ID: 28558708
[TBL] [Abstract][Full Text] [Related]
40. CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.
Jenkins MH; Brinckerhoff CE; Mullins DW
PLoS One; 2015; 10(3):e0121140. PubMed ID: 25798946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
